Current Potential Therapeutic Approaches against SARS-CoV-2: A Review.
Dharmendra Kumar YadavDesh Deepak SinghIhn HanYogesh KumarEun-Ha ChoiPublished in: Biomedicines (2021)
The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection and replication have been proposed. These medicines include inhibitors of serine protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2). The S protein of SARS-CoV-2 binds to the receptor in host cells. ACE2 inhibitors block TMPRSS2 and S protein priming, thus preventing SARS-CoV-2 entry to host cells. Moreover, antiviral medicines (including the nucleotide analogue remdesivir, the HIV protease inhibitors lopinavir and ritonavir, and wide-spectrum antiviral antibiotics arbidol and favipiravir) have been shown to reduce the dissemination of SARS-CoV-2 as well as morbidity and mortality associated with COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- angiotensin converting enzyme
- public health
- angiotensin ii
- induced apoptosis
- cell cycle arrest
- antiretroviral therapy
- human immunodeficiency virus
- coronavirus disease
- hiv positive
- binding protein
- hepatitis c virus
- cell death
- endoplasmic reticulum stress
- small molecule
- south africa
- signaling pathway
- combination therapy
- amino acid
- smoking cessation